27th May 2015 08:01
LONDON (Alliance News) - Pharmaceutical company Alliance Pharma PLC on Wednesday said trading in the first four months of 2015 has been satisfactory, with good growth from its Hydromol skin care brand and an in-line performance for its MacuShield eye care supplement.
Alliance Pharma said revenue in the first four months of the year was up 6% year-on-year to GBP15.6 million, boosted by a 14% rise in Hydromol sales and a 12% rise in MacuShield sales in the three months following its acquisition.
The group said it continues to expect supplies of ImmuCyst, its bladder cancer drug, to resume in the second half of the year. The company has been unable to supply ImmuCyst since production was halted at Sanofi SA's manufacturing plant in Canada in mid-2012, after US Food and Drug Administration inspectors cited the plant due to mould problems.
Shares in Alliance Pharma were down 0.5% to 43.525 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Alliance Pharma